Chemomab Therapeutics (CMMB) Capital Expenditures Growth (3y) (2021 - 2023)

Chemomab Therapeutics (CMMB) Capital Expenditures Growth (3y) (2021 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -12.25%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 46.88%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 8.97%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Chemomab Therapeutics 729.63 Mn 719.26 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 81.71%
Jun 30, 2023 -37.00%
Mar 31, 2023 -53.58%
Dec 31, 2022 -6.47%
Sep 30, 2022 36.10%
Jun 30, 2022 16.08%
Mar 31, 2022 -55.32%
Dec 31, 2021 -30.55%